Could Omvoh offer relief from recurring symptoms of UC, like bowel urgency?
Watch Dr. Alissa Walsh share her clinical experience of prescribing Omvoh to TREAT THE RECURRING SYMPTOMS of moderately to severely active UC
How can you help your patients improve their treatment outcomes?
Dr. Tim Raine spotlights Omvoh’s EXTENDED INDUCTION DOSING
How might patients with moderately to severely active UC benefit from Omvoh?
Watch Prof. Sebastian Zeissig share his Omvoh experience and the BENEFITS IT OFFERED TO HIS PATIENT WITH UC
Are you achieving long term remission in your patients with UC?
Prof. Peter Irving spotlights the 3 YEAR LONG TERM OUTCOMES with Omvoh
Indication:
Omvoh (mirikizumab) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
For full information see Omvoh physician leaflet approved by the Israeli MOH.
© 2025 Eli Lilly Israel. All rights reserved. PP-MR-IL-0163
הירשמו לקבלת עדכונים בנושאים שעלו בכתבה
תגובות אחרונות